(CVS) CVS Health - Ratings and Ratios
Insurance, Pbm, Retail, Specialty, Pharmacy
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 4.17% |
| Yield on Cost 5y | 5.19% |
| Yield CAGR 5y | 7.39% |
| Payout Consistency | 96.5% |
| Payout Ratio | 38.8% |
| Risk via 5d forecast | |
|---|---|
| Volatility | 36.3% |
| Value at Risk 5%th | 53.8% |
| Relative Tail Risk | -10.01% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.51 |
| Alpha | 48.54 |
| CAGR/Max DD | 0.00 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.509 |
| Beta | 0.326 |
| Beta Downside | 0.594 |
| Drawdowns 3y | |
|---|---|
| Max DD | 48.08% |
| Mean DD | 20.18% |
| Median DD | 20.34% |
Description: CVS CVS Health December 02, 2025
CVS Health Corp. (NYSE: CVS) delivers a full-stack of health-care solutions in the United States through three operating segments: Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness. The Benefits unit provides a range of insurance products-including medical, pharmacy, dental, behavioral health, Medicare Advantage, Medicare Supplement, PDPs, and Medicaid management-to employers, individuals, labor groups, and government-sponsored plans. The Health Services arm operates the company’s pharmacy-benefit-management (PBM) platform, handling formulary design, retail and specialty pharmacy networks, mail-order fulfillment, and disease-management services for a broad sponsor base. The Pharmacy & Consumer Wellness segment sells prescription and over-the-counter drugs, health-and-beauty products, and operates retail pharmacies, online channels, long-term-care (LTC) sites, and specialty infusion services.
In FY 2023 CVS generated $322 billion in revenue, with the Pharmacy & Consumer Wellness segment contributing roughly 55 % of sales and the PBM-driven Health Services segment delivering a 30 % margin on its $70 billion in pharmacy-benefit-management fees. The company’s same-store sales grew 5.2 % YoY, while its Medicare Advantage enrollment rose 7 % in a market where the aging U.S. population and rising chronic-disease prevalence are expanding demand for integrated care. Regulatory trends-such as ongoing Medicare Part D rebate reforms and state-level drug-price transparency rules-remain material drivers of CVS’s cost structure and pricing power.
For a deeper quantitative view, you may want to explore CVS’s valuation metrics and scenario analyses on ValueRay.
Piotroski VR‑10 (Strict, 0-10) 3.0
| Net Income (469.0m TTM) > 0 and > 6% of Revenue (6% = 23.65b TTM) |
| FCFTA 0.02 (>2.0%) and ΔFCFTA 1.80pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue -3.95% (prev -4.69%; Δ 0.73pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.04 (>3.0%) and CFO 9.11b > Net Income 469.0m (YES >=105%, WARN >=100%) |
| Net Debt (72.65b) to EBITDA (10.60b) ratio: 6.85 <= 3.0 (WARN <= 3.5) |
| Current Ratio 0.83 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (1.27b) change vs 12m ago 0.79% (target <= -2.0% for YES) |
| Gross Margin 13.88% (prev 14.20%; Δ -0.32pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 155.2% (prev 146.1%; Δ 9.08pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 1.94 (EBITDA TTM 10.60b / Interest Expense TTM 3.09b) >= 6 (WARN >= 3) |
Altman Z'' 1.15
| (A) -0.06 = (Total Current Assets 77.11b - Total Current Liabilities 92.69b) / Total Assets 255.33b |
| (B) 0.23 = Retained Earnings (Balance) 59.11b / Total Assets 255.33b |
| (C) 0.02 = EBIT TTM 5.99b / Avg Total Assets 253.88b |
| (D) 0.60 = Book Value of Equity 109.70b / Total Liabilities 182.22b |
| Total Rating: 1.15 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 52.43
| 1. Piotroski 3.0pt |
| 2. FCF Yield 3.60% |
| 3. FCF Margin 1.60% |
| 4. Debt/Equity 1.12 |
| 5. Debt/Ebitda 6.85 |
| 6. ROIC - WACC (= -1.10)% |
| 7. RoE 0.62% |
| 8. Rev. Trend 96.84% |
| 9. EPS Trend -62.11% |
What is the price of CVS shares?
Over the past week, the price has changed by -2.12%, over one month by +0.40%, over three months by -2.61% and over the past year by +57.74%.
Is CVS a buy, sell or hold?
- Strong Buy: 13
- Buy: 8
- Hold: 7
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the CVS price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 95 | 20.8% |
| Analysts Target Price | 95 | 20.8% |
| ValueRay Target Price | 90.5 | 15.1% |
CVS Fundamental Data Overview January 13, 2026
P/E Forward = 11.2108
P/S = 0.2602
P/B = 1.3978
P/EG = 0.5689
Revenue TTM = 394.08b USD
EBIT TTM = 5.99b USD
EBITDA TTM = 10.60b USD
Long Term Debt = 60.51b USD (from longTermDebt, last quarter)
Short Term Debt = 7.24b USD (from shortTermDebt, last quarter)
Debt = 81.75b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 72.65b USD (from netDebt column, last quarter)
Enterprise Value = 174.59b USD (101.94b + Debt 81.75b - CCE 9.10b)
Interest Coverage Ratio = 1.94 (Ebit TTM 5.99b / Interest Expense TTM 3.09b)
EV/FCF = 27.74x (Enterprise Value 174.59b / FCF TTM 6.29b)
FCF Yield = 3.60% (FCF TTM 6.29b / Enterprise Value 174.59b)
FCF Margin = 1.60% (FCF TTM 6.29b / Revenue TTM 394.08b)
Net Margin = 0.12% (Net Income TTM 469.0m / Revenue TTM 394.08b)
Gross Margin = 13.88% ((Revenue TTM 394.08b - Cost of Revenue TTM 339.39b) / Revenue TTM)
Gross Margin QoQ = 13.42% (prev 13.74%)
Tobins Q-Ratio = 0.68 (Enterprise Value 174.59b / Total Assets 255.33b)
Interest Expense / Debt = 0.96% (Interest Expense 784.0m / Debt 81.75b)
Taxrate = 25.41% (1.56b / 6.15b)
NOPAT = 4.47b (EBIT 5.99b * (1 - 25.41%))
Current Ratio = 0.83 (Total Current Assets 77.11b / Total Current Liabilities 92.69b)
Debt / Equity = 1.12 (Debt 81.75b / totalStockholderEquity, last quarter 72.93b)
Debt / EBITDA = 6.85 (Net Debt 72.65b / EBITDA 10.60b)
Debt / FCF = 11.55 (Net Debt 72.65b / FCF TTM 6.29b)
Total Stockholder Equity = 75.70b (last 4 quarters mean from totalStockholderEquity)
RoA = 0.18% (Net Income 469.0m / Total Assets 255.33b)
RoE = 0.62% (Net Income TTM 469.0m / Total Stockholder Equity 75.70b)
RoCE = 4.40% (EBIT 5.99b / Capital Employed (Equity 75.70b + L.T.Debt 60.51b))
RoIC = 3.16% (NOPAT 4.47b / Invested Capital 141.53b)
WACC = 4.26% (E(101.94b)/V(183.69b) * Re(7.11%) + D(81.75b)/V(183.69b) * Rd(0.96%) * (1-Tc(0.25)))
Discount Rate = 7.11% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -33.33 | Cagr: -0.93%
[DCF Debug] Terminal Value 83.64% ; FCFF base≈4.45b ; Y1≈3.52b ; Y5≈2.34b
Fair Price DCF = N/A (negative equity: EV 72.04b - Net Debt 72.65b = -616.1m; debt exceeds intrinsic value)
EPS Correlation: -62.11 | EPS CAGR: -48.32% | SUE: -2.85 | # QB: 0
Revenue Correlation: 96.84 | Revenue CAGR: 8.18% | SUE: 0.43 | # QB: 0
EPS next Quarter (2026-03-31): EPS=2.25 | Chg30d=-0.110 | Revisions Net=-9 | Analysts=20
EPS next Year (2026-12-31): EPS=7.17 | Chg30d=+0.006 | Revisions Net=+4 | Growth EPS=+7.6% | Growth Revenue=+2.5%
Additional Sources for CVS Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle